Sees FY25 adjusted EBITDA $180M-$260M. Comments taken from Q4 earnings conference call.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO:
- Alvotech Appoints New Chief Strategy Officer to Strengthen Market Position
- Alvotech Achieves Record 2024 Financial Results and Expands Biosimilar Pipeline
- Alvotech appoints Balaji Prasad as chief strategy officer
- Alvotech’s Biosimilar to Xolair Gains UK Regulatory Acceptance
- Alvotech Expands with Acquisition of Xbrane’s R&D Operations